207 related articles for article (PubMed ID: 22918164)
41. Immunophenotyping on simultaneously occurring plaques and tumours in mycosis fungoides and Sézary syndrome.
Preesman AH; Toonstra J; van der Putte SC; van Vloten WA
Br J Dermatol; 1993 Dec; 129(6):660-6. PubMed ID: 8286248
[TBL] [Abstract][Full Text] [Related]
42. Locomotion of T cells from patients with cutaneous T-cell lymphoma (Sézary syndrome and mycosis fungoides).
Gupta S; Safai B; Edelson R; Parrott D; Good R
Cell Immunol; 1980 Mar; 50(1):195-201. PubMed ID: 6967357
[No Abstract] [Full Text] [Related]
43. Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7- T helper lymphocytes expansion.
Scala E; Russo G; Cadoni S; Narducci MG; Girardelli CR; De Pità O; Puddu P
J Invest Dermatol; 1999 Oct; 113(4):622-7. PubMed ID: 10504451
[TBL] [Abstract][Full Text] [Related]
44. Immunophenotypic shift in a case of mycosis fungoides with vitreous invasion.
Lois N; Hiscott PS; Nash J; Wong D
Arch Ophthalmol; 2000 Dec; 118(12):1692-4. PubMed ID: 11115267
[TBL] [Abstract][Full Text] [Related]
45. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
[TBL] [Abstract][Full Text] [Related]
46. T-cell lymphoma: morphology, immunophenotype and clinical features.
Krajewski AS; Myskow MW; Cachia PG; Salter DM; Sheehan T; Dewar AE
Histopathology; 1988 Jul; 13(1):19-41. PubMed ID: 3061921
[TBL] [Abstract][Full Text] [Related]
47. Patch tests in Sézary syndrome and mycosis fungoides.
Shupp DL; Winkelmann RK
Contact Dermatitis; 1985 Sep; 13(3):180-5. PubMed ID: 4053598
[TBL] [Abstract][Full Text] [Related]
48. [Sézary syndrome. Clinical, immunological and proliferative kinetics].
Marosi L; Hofer F; Schwarzmeier J; Konrad K; Knapp W; Radaskiewicz T
Acta Med Austriaca; 1979; 6(5):237-40. PubMed ID: 318012
[TBL] [Abstract][Full Text] [Related]
49. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells.
Lyapichev KA; Bah I; Huen A; Duvic M; Routbort MJ; Wang W; Jorgensen JL; Medeiros LJ; Vega F; Craig FE; Wang SA
Cytometry B Clin Cytom; 2021 Mar; 100(2):183-191. PubMed ID: 32667737
[TBL] [Abstract][Full Text] [Related]
50. Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides.
Cetinözman F; Jansen PM; Vermeer MH; Willemze R
Arch Dermatol; 2012 Dec; 148(12):1379-85. PubMed ID: 23247480
[TBL] [Abstract][Full Text] [Related]
51. The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome.
Bi MY; Curry JL; Christiano AM; Hordinsky MK; Norris DA; Price VH; Duvic M
J Am Acad Dermatol; 2011 Jan; 64(1):53-63. PubMed ID: 21036417
[TBL] [Abstract][Full Text] [Related]
52. Intertriginous mycosis fungoides with T follicular helper cell phenotype progressing to Sézary syndrome.
Amir Ali A; Shameli A; Zhang C; Gniadecki R; Street L; Hardin J
Clin Exp Dermatol; 2022 Apr; 47(4):751-753. PubMed ID: 34798679
[TBL] [Abstract][Full Text] [Related]
53. Single-Cell RNA Sequencing Unveils the Clonal and Transcriptional Landscape of Cutaneous T-Cell Lymphomas.
Gaydosik AM; Stonesifer CJ; Khaleel AE; Geskin LJ; Fuschiotti P
Clin Cancer Res; 2022 Jun; 28(12):2610-2622. PubMed ID: 35421230
[TBL] [Abstract][Full Text] [Related]
54. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
55. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
56. It is time to adopt a multicolor immunophenotyping approach to evaluate blood for Sézary syndrome and mycosis fungoides.
Craig FE
Cytometry B Clin Cytom; 2021 Mar; 100(2):125-128. PubMed ID: 32083391
[No Abstract] [Full Text] [Related]
57. TIGIT and Helios Are Highly Expressed on CD4
Jariwala N; Benoit B; Kossenkov AV; Oetjen LK; Whelan TM; Cornejo CM; Takeshita J; Kim BS; Showe LC; Wysocka M; Rook AH
J Invest Dermatol; 2017 Jan; 137(1):257-260. PubMed ID: 27592800
[No Abstract] [Full Text] [Related]
58. Adult T-cell leukemia/lymphoma and cutaneous T-cell lymphoma. Are they related?
Yamada M; Takigawa M; Iwatsuki K; Inoue F
Int J Dermatol; 1989 Mar; 28(2):107-13. PubMed ID: 2786860
[TBL] [Abstract][Full Text] [Related]
59. Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants.
Edelson RL
J Am Acad Dermatol; 1980 Feb; 2(2):89-106. PubMed ID: 6988470
[TBL] [Abstract][Full Text] [Related]
60. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
